Reinsurance Group of America, (RGA) Is At $148.41 Formed Wedge; Arena Pharmaceuticals (ARNA) Shorts Up By 71.82%

June 12, 2018 - By Shannon Black

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Logo

Arena Pharmaceuticals Inc (NASDAQ:ARNA) had an increase of 71.82% in short interest. ARNA’s SI was 3.19 million shares in June as released by FINRA. Its up 71.82% from 1.86 million shares previously. With 4.25 million avg volume, 1 days are for Arena Pharmaceuticals Inc (NASDAQ:ARNA)’s short sellers to cover ARNA’s short positions. The SI to Arena Pharmaceuticals Inc’s float is 8.15%. The stock increased 1.08% or $0.52 during the last trading session, reaching $48.87. About 409,274 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has risen 233.31% since June 12, 2017 and is uptrending. It has outperformed by 220.74% the S&P500. Some Historical ARNA News: ; 11/05/2018 – Arena Pharma Presenting at UBS Conference May 22; 19/03/2018 – ARENA – TRIAL MET PRIMARY, SECONDARY ENDPOINTS WITH STATISTICAL SIGNIFICANCE FOR PATIENTS GETTING HIGH DOSE ETRASIMOD FOR 12 WKS; 26/03/2018 – Arena Pharmaceuticals Announces Completion of Public Offering of Common Stk and Exercise in Full of Underwriters’ Option to Purchase Additional Shrs; 22/03/2018 – ARNA to Trade, DBX, STG to Price: Equity Capital Markets; 19/03/2018 – Arena Pharma: Safety Results Support Potential Best-In-Class Profile; 14/03/2018 – ARENA PHARMA 4Q LOSS/SHR 35C, EST. LOSS/SHR 58C; 19/03/2018 – ARNA: OASIS PHASE 2 MEETS PRIMARY, SECONDARY ENDPOINTS FOR 2MG; 19/03/2018 – ARENA PHARMACEUTICALS – HIGH DOSE ETRASIMOD GROUP ACHIEVED STATISTICALLY SIGNIFICANT IMPROVEMENT IN CLINICAL REMISSION IN STUDY; 21/05/2018 – Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the American Thoracic Soc; 21/05/2018 – Arena Pharma Presenting at UBS Conference Tomorrow

Reinsurance Group of America, Incorporated (RGA) formed wedge down with $142.47 target or 4.00% below today’s $148.41 share price. Reinsurance Group of America, Incorporated (RGA) has $9.58 billion valuation. The stock decreased 0.97% or $1.46 during the last trading session, reaching $148.41. About 131,024 shares traded. Reinsurance Group of America, Incorporated (NYSE:RGA) has risen 19.99% since June 12, 2017 and is uptrending. It has outperformed by 7.42% the S&P500. Some Historical RGA News: ; 26/04/2018 – REINSURANCE GROUP 1Q ADJ BOOK VALUE/SHR $117.49; 26/04/2018 – Reinsurance Group 1Q Net $100.2M; 23/04/2018 – Reinsurance Group of America Names John J. Gauthier and Hazel M. McNeilage to Board; 23/04/2018 – RGA Appoints New Members to Board of Directors; 17/05/2018 – Fitch Affirms RGA Reinsurance Co.’s IFS Rating at ‘A’; Outlook Stable; 28/03/2018 – ADVISORY-Ignore stray alert on China Reinsurance Group’s FY results chain; 17/05/2018 – FITCH AFFIRMS RGA REINSURANCE IFS RATING AT ‘A’; OUTLOOK STABLE; 27/04/2018 – Consolidated Research: 2018 Summary Expectations for MGM Growth Properties, Reinsurance Group of America, Cincinnati Bell, GAIN; 26/04/2018 – Reinsurance Group of America Misses on EPS, Beats on Revenue; 29/03/2018 – A.M. Best Affirms Credit Ratings of Insurance Subsidiaries of Nassau Reinsurance Group Holdings, L.P

More notable recent Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on May 31, 2018, also Seekingalpha.com with their article: “Arena Pharmaceuticals’ (ARNA) CEO Presents at UBS Global Healthcare Brokers Conference (Transcript)” published on May 22, 2018, Seekingalpha.com published: “Arena Pharmaceuticals’ (ARNA) CEO Amit Munshi presents at Bank of America Merrill Lynch Healthcare Brokers …” on May 18, 2018. More interesting news about Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) were released by: Seekingalpha.com and their article: “Arena Pharmaceuticals’ (ARNA) CEO Amit Munshi on Q1 2018 Results – Earnings Call Transcript” published on May 15, 2018 as well as Streetinsider.com‘s news article titled: “RBC Capital Starts Arena Pharma (ARNA) at Outperform” with publication date: May 31, 2018.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $2.41 billion. The companyÂ’s proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It currently has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

Among 10 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Arena Pharmaceuticals had 27 analyst reports since October 28, 2015 according to SRatingsIntel. As per Monday, February 26, the company rating was maintained by Cantor Fitzgerald. The firm has “Buy” rating given on Thursday, January 4 by Cantor Fitzgerald. As per Monday, July 17, the company rating was maintained by Leerink Swann. On Wednesday, October 28 the stock rating was maintained by WallachBeth Capital with “Buy”. FBR Capital initiated the stock with “Outperform” rating in Thursday, September 15 report. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Buy” rating given on Tuesday, March 20 by Cantor Fitzgerald. The stock has “Buy” rating by Leerink Swann on Wednesday, January 17. Cantor Fitzgerald maintained it with “Buy” rating and $6500 target in Wednesday, April 18 report. On Wednesday, March 14 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Cantor Fitzgerald maintained the shares of ARNA in report on Tuesday, July 11 with “Buy” rating.

Among 11 analysts covering Reinsurance Group of America (NYSE:RGA), 2 have Buy rating, 1 Sell and 8 Hold. Therefore 18% are positive. Reinsurance Group of America has $171.0 highest and $87 lowest target. $150.40’s average target is 1.34% above currents $148.41 stock price. Reinsurance Group of America had 33 analyst reports since November 17, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Wednesday, October 19 by Deutsche Bank. The firm has “Hold” rating given on Friday, July 28 by RBC Capital Markets. Wells Fargo maintained it with “Hold” rating and $160.0 target in Tuesday, January 9 report. The rating was downgraded by JP Morgan on Tuesday, October 4 to “Neutral”. Deutsche Bank initiated the stock with “Buy” rating in Tuesday, January 5 report. The rating was initiated by Goldman Sachs with “Sell” on Tuesday, November 17. The rating was upgraded by Goldman Sachs on Friday, July 15 to “Buy”. Wood maintained the stock with “Hold” rating in Friday, April 7 report. The firm has “Neutral” rating given on Friday, October 7 by Credit Suisse. The rating was maintained by RBC Capital Markets with “Hold” on Monday, July 10.

Investors sentiment decreased to 0.97 in 2018 Q1. Its down 0.19, from 1.16 in 2017Q4. It fall, as 24 investors sold Reinsurance Group of America, Incorporated shares while 162 reduced holdings. 53 funds opened positions while 128 raised stakes. 56.76 million shares or 1.67% less from 57.73 million shares in 2017Q4 were reported. Prudential Financial Incorporated owns 379,138 shares. Moneta Grp Investment Advisors Ltd Liability Corporation owns 101 shares. Korea Inv Corporation has invested 0.05% in Reinsurance Group of America, Incorporated (NYSE:RGA). Envestnet Asset Mgmt holds 7,693 shares or 0% of its portfolio. Hermes Investment accumulated 0.94% or 417,992 shares. Northern has 0.03% invested in Reinsurance Group of America, Incorporated (NYSE:RGA). Moreover, Nuveen Asset Mngmt Ltd Liability Corporation has 0.04% invested in Reinsurance Group of America, Incorporated (NYSE:RGA) for 37,838 shares. State Treasurer State Of Michigan reported 23,500 shares. Eagle Boston Inv Mngmt Inc reported 0.03% stake. Tiaa Cref Limited Liability Co owns 255,825 shares. Boston Advsrs Ltd Limited Liability Company reported 13,442 shares. Highvista Strategies Lc invested in 0.1% or 1,600 shares. Qs Ltd holds 0% or 4 shares in its portfolio. Nj State Employees Deferred Compensation Plan invested in 0.08% or 2,829 shares. Paragon Capital Mngmt holds 0.12% or 1,833 shares.

Reinsurance Group of America, Incorporated (NYSE:RGA) Institutional Positions Chart